Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Hepatocellular Carcinoma Treatment and Prognosis, and Diet, Metabolism, and Disease.
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma.
MASLD Beyond the Liver: A Systemic Driver of Cardiovascular, Renal, and Oncologic Risk
STRmie-HD enables interruption-aware HTT repeat genotyping and somatic mosaicism profiling across sequencing platforms
Liver Transplant Outcomes in Patients With Transjugular Intrahepatic Portosystemic Shunt: A Retrospective Cohort Study With Propensity Score Analysis
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD.
A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis.
Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD
Impact of first and further decompensation in patients with compensated ACLD due to MASLD.
Carriage of rare pathogenic apob variants predispose to severe masld and hcc
Circulating histones as potential biomarkers of MASLD-MASH-HCC progression.
Diagnostic accuracy and cost-effectiveness of the CAR-OLT score in predicting cardiac risk for liver transplantation.
288<sup>th</sup> ENMC International Workshop. Towards better diagnosing, understanding and treating gastrointestinal symptoms in myotonic dystrophy: extended insights and practical recommendations. 16-18 May 2025, Hoofddorp, the Netherlands.
A potential age-independent MASLD-related liver fibrosis index based on metabolic profiling.
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study.
The Role of Endoscopic Ultrasound in Assessing Portal Hypertension: A State-of-the-Art Literature Review and Evolving Perspectives.
Liver Elastography for Liver Fibrosis Stratification: A Comparison of Three Techniques in a Biopsy-Controlled MASLD Cohort.
Metabolic dysfunction-associated steatotic liver disease in a tanzanian non-communicable diseases Population: Links to sugar-sweetened beverage intake
Phosphatidylethanol as a diagnostic and prognostic tool in steatotic liver disease: time to rethink alcohol consumption assessment.
Fibrosis and birthweight correlated with telomere shortening in paediatric metabolic dysfunction-associated steatotic liver disease
Multiparametric ultrasound for non-invasive assessment of liver steatosis, fibrosis, and inflammation in metabolic dysfunction-associated steatotic liver disease.
Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction.
Coronary Artery Disease Does Not Increase Risk of Cardiovascular Events and Mortality One Year After Liver Transplantation.
ITA-MASLD: A national observational study to characterize the profile of patients with MASLD in specialistic care in Italy.
Genome-wide association study of noninvasive scores of fibrotic MASLD in an Italian population
ITA-MASLD: A national observational study to characterize the profile of patients with MASLD in specialistic care in Italy
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.